



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of)
Durley, et al.) Attorney Docket No. 3300/1B
)
Serial No. 10/815,375) Group Art Unit: Unknown
)
Filed: April 1, 2004) Examiner: Unknown

For AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS

August 26, 2004

Commissioner of Patents
PO Box 1450
Alexandria, VA 22313

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith various documents cited on the attached Form PTO 1449. All documents cited on the attached Form PTO 1449 were already cited in a related application and are not resubmitted herewith. Applicants direct the Examiner to the related application(s) for documents previously submitted. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,

Philip B. Polster, II, Reg. No. 43,864
Attorney for Applicants
(314) 274-9094 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
P.O. Box 1027
Chesterfield, MO 63006



Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 3300/1B	APPLICATION NO.: 10/815,375
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Durley, et al.	
(Use several sheets if necessary)		Filed: 4/1/2004	Group:

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5,132,453	7/21/92	Griffith	562	560	03/23/91
	2	5,684,008	11/04/97	Hallinan et al	514	256	11/09/94
	3	5,830,917	11/30/98	Moore et al	514	634	09/11/95
	4	5,854,251	12/29/98	Hallinan et al	514	256	04/30/97
	5	5,863,931	01/26/99	Beams et al	514	357	06/22/94
	6	5,919,787	07/06/99	Hallinan et al	514	256	10/05/98
	7	5,945,408	08/31/99	Webber et al	514	63	08/08/96
	8	5,981,511	11/09/99	Gapud et al	514	63	03/05/97

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	9	WO 93/13055	07/08/93	PCT	C07C	257/14		
	10	WO 94/12165	06/09/94	PCT	A61K	31/155		
	11	WO 94/14780	07/07/94	PCT	C07D	239/48		
	12	WO 95/11014	04/27/95	PCT	A61K	31/00		
	13	WO 95/11231	04/27/95	PCT	C07D	207/22		
	14	WO 95/25717	09/28/95	PCT	C07C	257/14		
	15	WO 96/15120	05/23/96	PCT	C07D	257/06		
	16	WO 96/35677	11/14/96	PCT	C07D	223/12		
	17	WO 96/33175	10/24/96	PCT	C07D	223/12		
	18	WO 97/06802	02/27/97	PCT	A61K	31/495		
	19	WO 99/46240	09/16/99	PCT	C07C	257/14		
	20	EP 0521471	10/25/00	EP	C07D	239/42		
	21	EP 0446699	05/31/00	EP	C07K	5/06		
	22	WO 99/62875	12/09/99	PCT	A61K 31	155		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)
Sheet 2 of 2

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 3300/1B	APPLICATION NO.: 10/815,375
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Durley, et al.	
(Use several sheets if necessary)		Filed: 4/1/2004	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	23	Jeanguenat et al; Stereoselective Chain Elongation at C-3 of Cysteine through 2,3-Dihydrothiazoles, Without Recemization. Preparation of 2-Amino-5-hydroxy-3-mercaptopropanoic Acid Derivatives J. Chem Soc. Perkin Trans.; 1; 2291-2298; 1991
	24	Pattenden et al; Enantioselective Synthesis of 2-Alkyl Substituted Cysteines; Tetrahedron; 49; 2131-2138; 1993
	25	Bredt et al; Isolation of Nitric Oxide Synthetase, a Calmodulin-Requiring Enzyme; Proc Natl Acad Sci USA; 87; 682-685; 1990
	26	Moore et al; 2-Iminopiperidine and Other 2-Iminoazaheterocycles as Potent Inhibitors of Human Nitric Oxide Synthase Isoforms; J. Med. Chem; 39; 669-672; 1996
	27	Misko et al; A Fluorometric Assay for the Measurement of Nitrite in Biological Samples; Analytical Biochemistry; 214; 11-16; 1993

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)



CERTIFICATE OF MAILING BY FIRST CLASS MAIL

Serial No. 10/815,375
Filing Date: 04/01/2004
Examiner: Unknown
Group Art Unit: Unknown
Docket No. 3300/1B

Date of Deposit: August 26, 2004

I hereby certify that these papers or fee is being deposited with the United States Post Office to Addressee service under 37 CFR 1.10 & 1.8 on the date indicated above and is addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

IDS Form 1449
IDS Statement
Post Card

Michelle Becker

(Typed or printed name of person mailing paper or fee)


(Signature of person mailing paper or fee)